MARKET

ACRS

ACRS

Aclaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.215
-0.065
-2.85%
Opening 14:50 08/12 EDT
OPEN
2.330
PREV CLOSE
2.280
HIGH
2.460
LOW
2.206
VOLUME
399.85K
TURNOVER
--
52 WEEK HIGH
3.340
52 WEEK LOW
0.7000
MARKET CAP
94.63M
P/E (TTM)
-1.3248
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACRS stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 3.500.

EPS

ACRS News

More
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
•First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis  •First Subject Dosed in Phase 2a Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Pat
GlobeNewswire · 5d ago
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 6d ago
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
Zacks · 07/08 13:43
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers Party City Holdco Inc. (NYSE: PRTY) rose 34.4% to $1.74 in pre-market trading after the company announced it regained compliance with NYSE continued listing standards.
Benzinga · 07/08 11:16
Aclaris gains ~8% after filing IND for ATI-1777 in dermatitis
Seeking Alpha - Article · 07/07 21:31
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical Soft JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
GlobeNewswire · 07/07 21:01

Industry

Biotechnology & Medical Research
+0.59%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About ACRS

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.
More

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.